LUX-Lung 7: A Phase IIb Trial of Afatinib(BIBW2992) Versus Gefitinib for the Treatment of 1st Line EGFR Mutation Positive Adenocarcinoma of the Lung

NCT01466660 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

319

Enrollment

INDUSTRY

Sponsor class

Conditions

Lung Neoplasms

Interventions

DRUG: Afatinib
DRUG: gefitinib

Sponsor

Boehringer Ingelheim